Key facts
- It has raised $111.0M; the latest was Later Stage VC ($77.0M) in Jan 2026.
- Notable investors include Johnson & Johnson Innovation - JLABS, Johnson & Johnson JJDC, MSA Capital, MPCi, Bayland Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for PAQ Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for PAQ Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PAQ Therapeutics
Operator of a biotechnology company intended to restore health and cure disease through autophagy. The company develops a novel class of small-molecule degraders through autophagosome-tethering compound technology capable of binding a diverse array of substrates to the autophagy pathway, enabling physicians to create cures and overcome serious diseases where therapeutic options are limited for patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 10
- Website
- paqtx.com/
- Ownership
- Privately Held (backing)
PAQ Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PAQ Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PAQ Therapeutics in its N-PORT filings yet. We sweep new filings monthly.